The SAB will also offer scientific guidance to shape long-term R&D strategies as AltruBio explores other potential indications where ALTB-268 could benefit patients and expands its pipeline. “We are ...
We are pleased to announce the completion of enrollment in our lead ELI-002 Phase 2 AMPLIFY-7P study. The speed of study enrollment exceeded our expectations, reflecting high levels of investigator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback